Uterine sarcoma – current perspectives
Open Access
- 1 August 2017
- journal article
- review article
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 9, 597-606
Abstract
Uterine sarcomas comprise a group of rare tumors with differing tumor biology, natural history and response to treatment. Diagnosis is often made following surgery for presumed benign disease. Currently, preoperative imaging does not reliably distinguish between benign leiomyomas and other malignant pathology. Uterine leiomyosarcoma is the most common sarcoma, but other subtypes include endometrial stromal sarcoma (low grade and high grade), undifferentiated uterine sarcoma and adenosarcoma. Clinical trials have shown no definite survival benefit of adjuvant radiotherapy or chemotherapy and have been hampered by the rarity and heterogeneity of these disease types. There is a role of adjuvant treatment in carefully selected cases following multidisciplinary discussion at sarcoma reference centers. In patients with metastatic disease, systemic chemotherapy can then be considered. There is activity of a number of agents, including doxorubicin, trabectedin, gemcitabine-based chemotherapy, eribulin and pazopanib. Patients should be considered for clinical trial entry where possible. Close international collaboration is important to allow progress in this group of diseases.Keywords
This publication has 60 references indexed in Scilit:
- Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcomaCancer, 2013
- Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas StudyJournal of Clinical Oncology, 2011
- MRI appearance of mesenchymal tumors of the uterusEuropean Journal of Radiology, 2010
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomasEuropean Journal of Cancer, 2010
- Does Radiotherapy or Lymphadenectomy Improve Survival in Endometrial Stromal Sarcoma?International Journal of Gynecological Cancer, 2009
- Phase II Study of Sorafenib in Patients With Metastatic or Recurrent SarcomasJournal of Clinical Oncology, 2009
- Prognostic factors and survival in 1396 patients with uterine leiomyosarcomasCancer, 2008
- Uterine sarcomas in breast cancer patients treated with tamoxifenInternational Journal of Gynecological Cancer, 2006
- Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) StudyGynecologic Oncology, 2004
- A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1985